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INTRODUCTION 
Among patients with HCV mono-infection, clearance of HCV RNA from serum 
at week 4 and 12 of treatment with pegylated interferon plus ribavirin is highly 
predictive of achieving a sustained virological response (SVR).[1, 2] Similar 
findings have been reported for HIV-HCV co-infected patients[3-5] but there are 
no data available on the influence of ribavirin dose on the positive predictive 
value of a negative serum HCV RNA at week 4 or 12.   
The objective of the randomised, multinational PARADIGM study was to 
compare the efficacy and safety of two ribavirin dosage regimens (800 mg/day 
and 1000/1200 mg/day) administered in combination with peginterferon alfa-2a 
(40KD) in HIV-HCV co-infected patients. HCV RNA levels were monitored 
throughout the study, which provides the opportunity to examine the predictive 
value of early clearance of HCV RNA for SVR.   
OBJECTIVE 
The objective of this analysis is to explore the impact of ribavirin dosing regimen 
on the time to undetectable HCV RNA and the predictive value of a rapid 
virological response (RVR) or early virological response (EVR) for SVR.  
METHODS 
Patients 
Patients eligible for PARADIGM were co-infected with HIV-HCV (genotype 1) 
infection with a serum HCV RNA titre >600 IU/mL who had not received 
previous interferon-based therapy for chronic hepatitis C.  
Patients were required to have stable HIV disease with a CD4+ cell count ≥100 
cells/mm3. Individuals on stable anti-retroviral therapy (ART) and those not 
requiring ART were both eligible.  
Treatment 
Patients were randomised (1:2) to receive 48 weeks of treatment with oral 
ribavirin at either a fixed standard dose of 800 mg/day or a higher dose (1000 
mg/day for patients with a body weight <75 kg, or 1200 mg/day for those with a 
body weight ≥75 kg) in combination with subcutaneous peginterferon alfa-2a 
(40KD) 180 µg/week (Figure 1). 
 
Figure 1. Study design  
Outcomes 
HCV RNA levels were assessed by COBAS® Ampliprep/COBAS® TaqMan® 
HCV test; detection limit 20 IU/mL, Roche Diagnostics) at baseline, at week 4, 
12, 24, and 48 during treatment and after 24 weeks of untreated follow-up 
(study week 72).   
RVR was defined as undetectable HCV RNA in serum at week 4. Complete 
EVR was defined as undetectable HCV RNA in serum at week 12. Partial EVR 
was defined as greater than 2-log10 drop in HCV RNA at week 12. SVR was 
defined as undetectable HCV RNA at the end of untreated follow-up (study 
week 72).   
  
RESULTS 
Among the overall population of 410 patients with HIV-HCV co-infection, 80% 
were male, 64% were Caucasian, 11% had bridging fibrosis or cirrhosis, 80% 
had an HCV-RNA level >800,000 IU/mL and 89% were receiving ART at 
baseline (Table 1).  
Table 1. Baseline characteristics of patients in PARADIGM  
  Peginterferon alfa 2a (40KD) plus: 
ribavirin 800 
mg/day  
(n=135) 
ribavirin 1000/1200 mg/day 
(n=275) 
Male gender, n (%) 106 (79) 224 (81) 
Mean age ± SD, years 45.2 ± 8.4 45.5 ± 8.2 
Mean weight ± SD, kg 77.2 ±14.1 78.0 ± 17.5 
Race/ethnicity, n (%) 
Non-Hispanic Caucasian 60 (44) 116 (42) 
Hispanic 33 (24) 76 (28) 
Hispanic Caucasian 26 (19) 60 (22) 
Hispanic non-Caucasian 7 (5) 16 (6) 
Non-Hispanic African American 40 (30) 77 (28) 
Other 2 (1) 6 (2) 
Alanine aminotransferase quotient ≤1.5, 
n (%) 
76 (56) 144 (52) 
Bridging fibrosis/cirrhosis, n (%) 16 (12) 30 (11) 
Child Pugh score >5, n (%) 2 (1) 6 (2) 
Mean HCV RNA ±  SD,  log10 IU/mL 6.4 ± 0.82 6.5 ± 0.90 
HCV RNA >800,000 IU/mL, n (%) 106 (79) 223 (81) 
Mean CD4+ cell count  ± SD, cells/mm
3 489 ± 243 519 ± 273 
CD4+ cell count <200/µl, n (%) 7 (5) 18 (7) 
On ART, n (%) 120 (89) 241 (88) 
  
SD = standard deviation; ART = anti-retroviral therapy  
A total of 120/135 (89%) and 243/275 (88%) patients randomised to 800 
mg/day and 1000/1200 mg/day of ribavirin completed the first 12 weeks of 
treatment.   
There was no statistically significant difference in the overall SVR rates between 
patients randomized to ribavirin 800 mg/day or 1000/1200 mg/day (19% versus 
22%, respectively, Figure 2).  
Figure 2. Overall SVR rates  
Rates of relapse (detectable HCV RNA during 24 weeks untreated follow-up 
among patients with an undetectable HCV RNA at the end of scheduled 
treatment) were similar between patients randomized to ribavirin 800 mg/day 
(32%) and 1000/1200 mg/day (36%).  
Among patients randomised to ribavirin 800 mg/day or 1000/1200 mg/day the 
rates of RVR (8% versus 7%, respectively) and complete EVR (26% in both 
groups) were similar. In contrast the partial EVR rate was somewhat lower 
among patients receiving the lower dose of ribavirin (25% versus 35% in 
patients randomised to 1000/1200 mg/day, Figure 3).   
 
Figure 3. Rates of RVR, complete EVR (cEVR) and partial EVR (pEVR)  
In both ribavirin dosage groups, achievement of an RVR or complete EVR was 
associated with a high probability (positive predictive value; PPV) of achieving 
an SVR. Conversely, patients with a slow response to treatment (partial EVR) 
had a low probability of achieving an SVR after 48 weeks of treatment 
regardless of the dose of ribavirin (Figure 4 and Table 2).  
 Figure 4. Rates of SVR in patients with an RVR, complete EVR (cEVR) and partial EVR 
(pEVR)  
Failure to achieve an on-treatment response defined as an RVR, cEVR or 
pEVR was also associated with a high probability of not achieving an SVR 
defined as the negative predictive value (NPV) (Table 2).   
  
Table 2. Positive and negative predictive values for on-treatment 
virological responses for SVR 
On-treatment response 
category 
Predictor Ribavirin 800 
mg/day 
Ribavirin 1000/1200 
mg/day 
RVR PPV 64% 75% 
NPV 85% 82% 
cEVR PPV 63% 66% 
NPV 96% 94% 
pEVR PPV 9% 13% 
NPV 77% 74% 
PPV = Positive predictive value defined as the probability a patients with an on-
treatment response achieving an SVR 
NPV = Negative predictive value defined as the probability that a patients 
without an on-treatment response not achieving an SVR  
CONCLUSIONS 
The use of a higher dose of ribavirin (1000/1200 mg/day) in combination with 
peginterferon alfa-2a (40KD) did not significantly increase on-treatment 
virological response rates or SVR rates in HIV-HCV co-infected patients with 
difficult-to-treat HCV genotype 1 infection in the PARADIGM study.   
Consistent with previous reports, achievement of rapid clearance of HCV RNA 
from serum at week 4 (RVR) and at week 12 (complete EVR) was highly 
predictive of SVR, regardless of the ribavirin dosing regimen, whereas failure to 
achieve a cEVR was highly predictive of not achieving an SVR.  
Some treatment guidelines recommend a longer 72-week course of treatment 
among patients with a partial EVR who go on to achieve an undetectable HCV 
RNA at week 24.[6]   
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